MedTrace Logo

Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies

NCT00599872 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 430

Last updated 2015-01-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine an effective dose range for the administration of ragweed allergenic extract via the sublingual route of administration

Conditions

  • Allergic Rhinitis

Interventions

BIOLOGICAL

Standardized Ragweed Allergenic Extract

Standardized Ragweed Allergenic Extract, sublingual oral

BIOLOGICAL

Placebo

Placebo, sublingual oral

Sponsors & Collaborators

  • Greer Laboratories

    lead INDUSTRY

Principal Investigators

  • Robert E. Esch, PhD · Greer Laboratories, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-11-30
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00599872 on ClinicalTrials.gov